Jaroslaw P. Maciejewski, MD, PhD, FACP

Jaroslaw P. Maciejewski, MD, PhD, FACP, is chairman of the Department of Translational Hematology and Oncology Research at Cleveland Clinic's Taussig Cancer Institute. He is also a professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine. Dr Maciejewski earned his MD and PhD from Humboldt University of Berlin in Germany. He completed his internal medicine residency at the University of Nevada, Reno School of Medicine and a hematology fellowship at the National Institutes of Health Clinical Center in Bethesda, MD. He also completed a postdoctoral research fellowship at the Hematology Branch of the National Heart, Lung, and Blood Institute, also in Bethesda.

Dr Maciejewski is an attending hematologist specializing in bone marrow failure syndromes, inherited and acquired cytopenias, and myelodysplastic syndrome; he sees patients from all over the United States. His research-specific interests have evolved from molecular and immune mechanisms of bone marrow failure syndromes, including myelodysplastic syndromes, leukemia genetics, and targeted drug discovery for these conditions. His laboratory has made several important contributions to the understanding of hematologic diseases, such as the immunogenetic underpinnings of immune-mediated and idiopathic bone marrow failure syndromes, including the pathogenesis of aplastic anemia, paroxysmal nocturnal hemoglobinuria, and large granular lymphocytic leukemia. His work contributed to the application of single nucleotide polymorphism arrays for karyotyping and the clinical use of next-generation sequencing in bone marrow failure.

These studies have led to the discovery of various pivotal somatic and germline mutations and secondary mechanistic and clinical research lines. The most notable among them are his involvement in the discovery of TET2 mutations and the original discovery of CBL, SETBP1, and DDX41 mutations in myeloid neoplasia, among many others. Over the last few years, Dr Maciejewski's genetic studies have been highly translational and have been directed toward the identification of molecular lesions to be applied in diagnostics or for rational drug discovery. Bone marrow failure syndromes have also served as a medical canvas for investigations of hematopoietic stem cells in disease, aging, regeneration, and bone marrow transplantation. 

Dr Maciejewski has more than 450 publications and is a member of numerous professional societies, including the American Society of Hematology, the American Society for Clinical Investigation, the Association of American Physicians, and the American College of Physicians.